camptothecin has been researched along with Anoxemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dong, C; Huang, B; Li, C; Lu, B; Ma, Q; Shen, Y; Sun, P; Xiang, H; Zhuang, F | 1 |
| Du, L; Lin, Z; Liu, JY; Lu, ZY; Luo, CM; Wen, LF; Yang, DC | 1 |
| Lin, Z; Liu, JY; Luo, CM; Wen, LF; Yang, DC; Yang, XZ | 1 |
| Chen, J; Chen, M; Hou, Y; Jia, N; Li, R; Meng, W; Sun, B; Tang, X; Zhang, W | 1 |
| Jin, C; Lu, W; Zhang, Q | 1 |
| Chang, LL; Dai, XY; Gai, RH; He, QJ; Wang, DD; Yang, B; Zhou, TY; Zhu, DF; Zhu, H; Zhuang, LH | 1 |
| Chen, RM; Lin, CJ; Lin, YL; Luh, F; Yen, Y | 1 |
| Ishikawa, E; Kamiyama, H; Mashiko, R; Matsumura, A; Osuka, S; Takano, S | 1 |
| Azrak, R; Bhattacharya, A; Cao, S; Durrani, FA; Mazurchuk, R; Pendyala, L; Rustum, YM; Slocum, HK; Spernyak, JA; Tóth, K | 1 |
| Adams, DJ | 1 |
| Colige, AC; Deroanne, CF; Dubail, J; Habraken, Y; Kesteloot, F; Lambert, CA; Lapière, CM; Mineur, P; Noël, A; Nusgens, BV; Vöö, S; Waltenberger, J | 1 |
| Cao, Y; Desjardins, A; Dewhirst, MW; Friedman, HS; Herndon, JE; Marcello, JE; McLendon, RE; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Diana, A; Diaz, G; Gremo, F; Isola, R; Murru, R; Setzu, MD; Sogos, V; Zucca, A | 1 |
| Aller, P; de Blas, E; Fernández, C; Sancho, P; Troyano, A | 1 |
1 review(s) available for camptothecin and Anoxemia
| Article | Year |
|---|---|
The impact of tumor physiology on camptothecin-based drug development.
Topics: Acidosis; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Hydrogen-Ion Concentration; Hypoxia; Male; Neoplasms | 2005 |
1 trial(s) available for camptothecin and Anoxemia
| Article | Year |
|---|---|
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Female; Humans; Hypoxia; Irinotecan; Male; Middle Aged; Neovascularization, Pathologic; Proportional Hazards Models; Radiography; Retrospective Studies; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
12 other study(ies) available for camptothecin and Anoxemia
| Article | Year |
|---|---|
Sequential Ultrasound-Triggered and Hypoxia-Sensitive Nanoprodrug for Cascade Amplification of Sonochemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Hypoxia; Nanoparticles; Neoplasms; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment; Ultrasonic Therapy | 2022 |
A Hypoxia-Activated Prodrug Conjugated with a BODIPY-Based Photothermal Agent for Imaging-Guided Chemo-Photothermal Combination Therapy.
Topics: Azo Compounds; Boron; Boron Compounds; Camptothecin; Cell Line, Tumor; Humans; Hyperthermia, Induced; Hypoxia; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Porphobilinogen; Prodrugs | 2022 |
A promising strategy for synergistic cancer therapy by integrating a photosensitizer into a hypoxia-activated prodrug.
Topics: Camptothecin; Cell Line, Tumor; Humans; Hypoxia; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Prodrugs | 2022 |
GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy
Topics: Breast Neoplasms; Camptothecin; Disulfides; Female; Glutathione; Gold; Humans; Hyaluronic Acid; Hypoxia; Prodrugs; Tumor Microenvironment | 2023 |
Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Design; Ether; Humans; Hypoxia; Irinotecan; Methods; Mice; Microsomes, Liver; Prodrugs; Structure-Activity Relationship | 2017 |
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunoenzyme Techniques; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Phosphoproteins; Protein Transport; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Camptothecin; Carbonic Anhydrase IX; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclodextrins; Female; Glioblastoma; Glioma; Humans; Hypoxia; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoconjugates; Nanomedicine; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Polyethylene Glycols; Tight Junctions; Xenograft Model Antitumor Assays | 2016 |
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Proliferation; Glioma; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Irinotecan; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Squamous Cell; Cell Differentiation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypoxia; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Nude; Microcirculation; Oxygen; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents.
Topics: Animals; Apoptosis; Camptothecin; DNA Damage; Enzyme Inhibitors; Gene Expression; Glycosylation; Humans; Hypoglycemia; Hypoxia; Mice; Mice, Nude; Mutagens; Neovascularization, Pathologic; Protein Isoforms; Reactive Oxygen Species; RNA, Messenger; Swine; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2007 |
Subcellular heterogeneity of mitochondrial membrane potential: relationship with organelle distribution and intercellular contacts in normal, hypoxic and apoptotic cells.
Topics: Animals; Apoptosis; Astrocytes; Camptothecin; Cell Line; Chlorocebus aethiops; Cytoplasm; Enzyme Inhibitors; Glutamic Acid; Humans; Hypoxia; Intracellular Membranes; Membrane Potentials; Mitochondria; Organelles; Sodium Chloride; Vero Cells | 1999 |
Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation.
Topics: Adenosine Triphosphate; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Buthionine Sulfoximine; Camptothecin; Cell Death; Cisplatin; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Enzyme Inhibitors; Etoposide; Flow Cytometry; Glutathione; Humans; Hydrogen Peroxide; Hypoxia; Immunoblotting; Melphalan; Membrane Potentials; Mitochondria; Monocytes; Necrosis; Nucleic Acid Synthesis Inhibitors; Oxygen; Radiation-Protective Agents; Reactive Oxygen Species; Spectrometry, Fluorescence; Time Factors; Topoisomerase I Inhibitors; U937 Cells | 2001 |